Marinomed Biotech Finalizes Carragelose Business Sale to Unither

Marinomed Biotech AG has successfully closed the sale of its Carragelose business to Unither Pharmaceuticals. The transaction, approved by shareholders on December 19, 2024, includes an upfront payment of EUR 5 million. The overall deal could amount to EUR 20 million, contingent on future milestones. The companies have also signed a transition service agreement.

This strategic move allows Marinomed to focus on its Marinosolv assets, boosting innovation in immune disorder treatments. Meanwhile, Unither aims to expand its product portfolio in respiratory health and ophthalmology using Carragelose, a virus-blocking compound derived from red seaweed.